Featuring perspectives from Prof Giuseppe Curigliano, Prof Nadia Harbeck, Dr Ian E Krop, Dr Nancy U Lin and Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Prof Harbeck (1:39) Case: A woman in her mid 50s presents with locally advanced ER-positive, HER2-positive breast cancer — Alan B Astrow, MD (12:52) Case: A woman in her mid 40s with ER-positive, HER2-positive Stage II breast cancer s/p neoadjuvant TCHP with residual disease receives adjuvant T-DM1 but discontinues due to neuropathy — Laila Agrawal, MD (20:02) Previously Untreated HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (25:10) Case: A woman in her early 80s presents with de novo metastatic (bone-only) ER-positive, HER2-positive breast cancer — Zanetta S Lamar, MD (35:03) Optimal Management of Brain Metastases in Patients with HER2-Positive Breast Cancer — Dr Lin (46:20) Case: A woman in her early 60s with ER-positive, HER2-positive breast cancer develops a cerebellar metastasis while receiving adjuvant anastrozole after prior anti-HER2 therapy — Justin Favaro, MD, PhD (59:41) Case: A woman in her early 40s with ER-negative, HER2-positive mBC develops a headache shortly after neoadjuvant TCHP, surgery and postneoadjuvant T-DM1 and is found to have an isolated 4-cm brain metastasis — Dr Agrawal (1:05:36) Selection and Sequencing of Therapy for Relapsed/Refractory HER2-Positive mBC in the Absence of CNS Involvement — Dr Krop (1:12:00) Case: A woman in her early 40s with ER-positive, HER2-positive mBC receives THP (docetaxel/trastuzumab/pertuzumab) and maintenance tucatinib with trastuzumab/pertuzumab on a clinical trial and now has disease progression — Yanjun Ma, MD, PhD (1:23:04) Tolerability Considerations with HER2-Targeted Therapies — Dr O'Shaughnessy (1:29:32) Case: A woman in her mid 60s presents with localized ER-negative, HER2-positive infiltrating ductal carcinoma — Erik Rupard, MD (1:46:06) Case: A woman in her early 70s with recurrent ER-positive, HER2-positive mBC receives trastuzumab deruxtecan (T-DXd) and has concerning pulmonary symptoms but without findings on diagnostic imaging — Kimberly Ku, MD Case: A woman in her mid 40s with ER-positive, HER2-positive breast cancer metastatic to the brain and lung who received multiple prior treatments responds to T-DXd but develops Grade 1 interstitial lung disease — Richard Zelkowitz, MD (1:49:49) CME information and select publications
